Emergent BioSolutions (NYSE:EBS) Cut to “Hold” at StockNews.com

Emergent BioSolutions (NYSE:EBS) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Friday.

EBS has been the subject of several other research reports. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research report on Tuesday. Benchmark raised their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th.

Emergent BioSolutions Price Performance

Shares of NYSE:EBS traded up $0.13 during trading on Friday, reaching $11.61. The stock had a trading volume of 1,241,520 shares, compared to its average volume of 1,077,335. The business’s 50-day moving average price is $9.39 and its 200 day moving average price is $9.31. Emergent BioSolutions has a 52 week low of $1.42 and a 52 week high of $15.10. The stock has a market capitalization of $629.19 million, a PE ratio of -2.83 and a beta of 1.60. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.37 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.88. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The company had revenue of $293.80 million for the quarter, compared to analyst estimates of $328.72 million. During the same quarter in the previous year, the firm earned ($1.44) earnings per share. As a group, equities analysts predict that Emergent BioSolutions will post -0.63 earnings per share for the current year.

Institutional Trading of Emergent BioSolutions

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Personalized Indexing Management LLC bought a new position in shares of Emergent BioSolutions in the 2nd quarter valued at about $93,000. Stifel Financial Corp bought a new position in Emergent BioSolutions in the third quarter valued at approximately $96,000. FORA Capital LLC bought a new position in Emergent BioSolutions in the third quarter valued at approximately $103,000. Landscape Capital Management L.L.C. acquired a new stake in Emergent BioSolutions during the 3rd quarter worth $141,000. Finally, Entropy Technologies LP bought a new stake in shares of Emergent BioSolutions during the 3rd quarter valued at $155,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.